This is a working overview of Somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
'My Street') urban redevelopment program and the residence renovation program. Through territorial expansion on 1 July 2012—southwest into the Moscow Oblast—the city's area more than doubled, increasing from 1,091 to 2,511 square kilometers (421 to 970 sq mi). As a result, Moscow became the largest city on the European continent by area; Moscow also grew in population by 233,000 people. The annexed territory was officially named Новая Москва (lit. 'New Moscow').
Antioxidants are compounds that inhibit oxidation, a chemical reaction that can produce free radicals. Antioxidants are frequently added to industrial products, such as polymers, fuels, and lubricants, to extend their usable lifetimes. Foods are also treated with antioxidants to prevent spoilage, in particular the rancidification of oils and fats. In cells, antioxidants such as glutathione, mycothiol, or bacillithiol, and enzyme systems like superoxide dismutase, inhibit damage from oxidative stress. Dietary antioxidants include vitamins A, C, and E. Dietary supplements marketed as antioxidants have not been shown to improve human health.
== Medical uses == The primary application for phentolamine is for the control of hypertensive emergencies, most notably due to pheochromocytoma. It also has usefulness in the treatment of cocaine-induced cardiovascular complications, where one would generally avoid β-blockers (e.g., metoprolol), as they can cause unopposed α-adrenergic mediated coronary vasoconstriction, worsening myocardial ischemia and hypertension. Phentolamine is not a first-line agent for this indication. Phentolamine should only be given to patients who do not fully respond to benzodiazepines, nitroglycerin, and calcium channel blockers. When given by injection, it causes blood vessels to dilate, thereby increasing blood flow. When injected into the penis (intracavernosal), it increases blood flow to the penis, which results in an erection. It may be stored in crash carts to counteract severe peripheral vasoconstriction secondary to extravasation of peripherally placed vasopressor infusions, typically of norepinephrine. Epinephrine infusions are less vasoconstrictive than norepinephrine as they primarily stimulate β receptor more than α receptors, but the effect remains dose-dependent. Phentolamine also has diagnostic and therapeutic roles in complex regional pain syndrome (CRPS). Phentolamine is marketed in the dental field as a local anesthetic reversal agent. Branded as OraVerse, it is a phentolamine mesylate injection designed to reverse the local vasoconstrictor properties used in many local anesthetics to prolong anesthesia.
The broadcast pattern covered an area of about 100 degrees in a roughly fan-shaped area, with a smaller side lobe to the rear, courtesy of the reflectors, and much smaller ones to the sides. When the signal reflected off the ground it underwent a ½ wavelength phase-change, which caused it to interfere with the direct signal. The result was a series of vertically stacked lobes about 5 degrees wide from 1 degree off the ground to the vertical. The system was later expanded by adding another set of four additional antennas closer to the ground, wired in a similar fashion. The receiver consisted of an Adcock array consisting of four 240 foot (73 m) tall wooden towers arranged at the corners of a square. Each tower had three sets (originally two) of receiver antennas, one at 45, 95 and 215 feet off the ground. The mean height of the transmitter stack was 215 feet, which is why the topmost antenna was positioned at the same altitude in order to produce a reception pattern that was identical to the transmission. A set of motor-driven mechanical switches allowed the operator to select which antenna was active. The output of the selected antenna on each of the four towers was sent to a single radiogoniometer system (not Watt's own huff-duff solution). By connecting the antennas together in X-Y pairs the horizontal bearing could be measured, while connecting together the upper and lower antennas allowed the same goniometer to be used to measure the vertical angle. Two physical layout plans were used, either 'East Coast' or 'West Coast'.
Other stressors that can stimulate increased solanine biosynthesis include mechanical damage, improper storage conditions, improper food processing, and sprouting. The largest concentration of solanine in response to stress is on the surface in the peel, making it an even better defense mechanism against pests trying to consume it.
Sources: en.wikipedia.org
Because the Solar Wind Spectrometer made continuous measurements, it was possible to measure how the Earth's magnetic field affects arriving solar wind particles. For about two-thirds of each orbit, the Moon is outside of the Earth's magnetic field. At these times, a typical proton density was 10 to 20 per cubic centimeter, with most protons having velocities between 400 and 650 kilometers per second. For about five days of each month, the Moon is inside the Earth's geomagnetic tail, and typically no solar wind particles were detectable. For the remainder of each lunar orbit, the Moon is in a transitional region known as the magnetosheath, where the Earth's magnetic field affects the solar wind, but does not completely exclude it. In this region, the particle flux is reduced, with typical proton velocities of 250 to 450 kilometers per second. During the lunar night, the spectrometer was shielded from the solar wind by the Moon and no solar wind particles were measured. Protons also have extrasolar origin from galactic cosmic rays, where they make up about 90% of the total particle flux. These protons often have higher energy than solar wind protons, and their intensity is far more uniform and less variable than protons coming from the Sun, the production of which is heavily affected by solar proton events such as coronal mass ejections. Research has been performed on the dose-rate effects of protons, as typically found in space travel, on human health.
== 3D structure == The overall fold of Rieske proteins, comprising two subdomains, is dominated by antiparallel β-structure and contains variable numbers of α-helices. The smaller "cluster-binding" subdomains in mitochondrial and chloroplast proteins are virtually identical, whereas the large subdomains are substantially different in spite of a common folding topology. The [Fe2S2] cluster-binding subdomains have the topology of an incomplete antiparallel β-barrel. One iron atom of the Rieske [Fe2S2] cluster in the domain is coordinated by two cysteine residues and the other is coordinated by two histidine residues through the Nδ atoms. The ligands coordinating the cluster originate from two loops; each loop contributes one Cys and one His.
== Bibliography == Silva, Robert J. (2006). "Fermium, Mendelevium, Nobelium, and Lawrencium" (PDF). In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Vol. 3 (3rd ed.). Dordrecht: Springer. pp. 1621–1651. doi:10.1007/1-4020-3598-5_13. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17.
== Structure == The secondary structure consists of 13 beta-pleated sheets, 2 alpha-helices, 2 310-helices, and 8 loop regions. In terms of amino acid sequences, hK6 is most similar to myelencephalon-specific protease (MSP), which comes from the rat kvllikrein gene family. MSP and hK6 both target the peptide bond where arginine follows and they both automatically cleave themselves at their Arg positions. However, structurally, hK6 most resembles trypsin found in cows/oxen. Surrounding the active site, there are short loop regions that point away from the binding site. In the binding site, residues 189-195, 214-220, and 224-228 are found in addition to the Asp, His, and Ser residues.
Sources: en.wikipedia.org
== Bibliography == Wagstaff, William Falkland Islands: The Bradt Travel Guide Patrick Watts quoted in Fox, Robert Eyewitness Falklands: A personal account of the Falklands campaign, 1982, p309. The Toponymy of the Falkland Islands as recorded on Maps and in Gazetteers The Permanent Committee on Geographical Names for British Official Use. Southby-Tailyour, Ewen – Falkland Island Shores The European (pub by British Union of Fascists), vol 8, issue 5 (January 1957 p 313-9) PRO HO 45/25740 "Jeffrey Hamm" (British Public Records)
The high degree of interconnectivity in monoliths confers an advantage seen in the low backpressures and readily achievable high flow rates. Monoliths are ideally suited for large molecules; although the purification of larger molecules can be very time-consuming. As mentioned previously, particle sizes are decreasing in an attempt to achieve higher resolution and faster separations, which led to higher backpressures. When the smaller particle sizes are used to separate biomolecules, backpressures increase further because of the large molecule size. In monoliths, where backpressures are low and channel sizes are large, small molecule separations are less efficient. This is demonstrated by the dynamic binding capacities, a measure of how much sample can bind to the surface of the stationary phase. Dynamic binding capacities of monoliths for large molecules can be an order of ten times greater than that for particulate packings. Monoliths exhibit no shear forces or eddying effects. High interconnectivity of the mesopores allows for multiple avenues of convective flow through the column. Mass transport of solutes through the column is relatively unaffected by flow rate. This is completely at odds to traditional particulate packings, whereby eddy effects and shear forces contribute greatly to the loss of resolution and capacity, as seen in the vanDeemter curve. Monoliths can, however, suffer from a different flow disadvantage: wall effects. Silica monoliths, especially, have a tendency to pull away from the sides of their column encasing.
Johnson, the Battlegroup commander; Commander John Stufflebeem, leader of the VFA-103 F-14 squadron; Lt Barry McKibben, of the tactical unit; the Northrop Grumman E-2 Hawkeye airborne early warning aircraft, with Lt Scotty Bruce, Tactical Coordination officer, who watched for unidentified 'bogies' - the E-2 could take control of the fighter aircraft for the best interception; the E-6A Prowler had electronic jamming and could launch the AGM-88 HARM missile; Lt Chris Heath, Prowler pilot and Lt Darryl Leinhardt, electronic countermeasures officer; the HOTAS and forward-looking infrared systems of the Hornet; Commander Richard Kurrus aircraft handling officer; on landing, pilots attempt to catch the third of four wires; the Harold Wilson government of the UK decided to retire the UK's large strike carriers in 1966, which may have prompted the Falklands War, as the Argentinians would not have contemplated such an invasion otherwise; the French have the largest Navy in Europe, with its Foch carrier, and the new Dassault Rafale aircraft; the Invincible class light aircraft carriers were not recognised by the American military as full aircraft carriers; Captain Fabian Malbon, commanding officer of the Invincible; the Nimitz class was heavily protected against incoming attacks; Colonel John Schmidt of the Marine Ground Force; Denis Healey, Secretary State of Defence from 1964–70 and his cancellation of new British carriers in 1966; Admiral of the Fleet Terence Lewin; Admiral Edward H.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.